---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-062656"
form_type: "8-K"
ticker: "SABS"
cik: "0001833214"
company_name: "SAB Biotherapeutics, Inc."
filed_at: "2024-05-21T23:59:59+00:00"
generated_at: "2026-06-01T11:21:56.099719+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# FDA clears IND for SAB Biotherapeutics' T1D therapy SAB-142 Phase 1 trial

## Summary
- FDA cleared IND for SAB-142, a human anti-thymocyte immunoglobulin for type 1 diabetes.
- Phase 1 HUMAN trial is randomized, double-blind, placebo-controlled, single-ascending dose (0.03-2.5 mg/kg).
- Enrollment of US patients with type 1 diabetes now permitted; third cohort dosed with no serum sickness.
- Topline results from the MELD-ATG study expected in 2025.
- SAB-142 aims to delay onset or progression of stage 3 type 1 diabetes.

## SEC filing metadata
- accession: 0000950170-24-062656
- form_type: 8-K
- ticker: SABS
- cik: 0001833214
- company_name: SAB Biotherapeutics, Inc.
- filed_at: 2024-05-21T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1833214/000095017024062656/0000950170-24-062656-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1833214/000095017024062656/sabs-20240521.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-062656
- JSON: https://secwatch.observer/filing/0000950170-24-062656.json
- Plain text: https://secwatch.observer/filing/0000950170-24-062656.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.